PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34271106-7	2021	(2) GA treatment up-regulated the expression and activity of NADPH oxidase and iNOS, and increased ROS/RNS productions (O2 -,  OH, NO and ONOO-) in the MDA-MB-231 cells; (3) GA down-regulated the expression of SLC7A11 of System Xc-, decreased glutathione (GSH) level and inhibited GPX activity.	18alpha-glycyrrhetinic acid	4-6	nitric oxide synthase 2	Homo sapiens	79-83	
34271106-7	2021	(2) GA treatment up-regulated the expression and activity of NADPH oxidase and iNOS, and increased ROS/RNS productions (O2 -,  OH, NO and ONOO-) in the MDA-MB-231 cells; (3) GA down-regulated the expression of SLC7A11 of System Xc-, decreased glutathione (GSH) level and inhibited GPX activity.	18alpha-glycyrrhetinic acid	174-176	nitric oxide synthase 2	Homo sapiens	79-83	
34271106-8	2021	Taken together, GA could promote the productions of ROS and RNS via activating NADPH oxidases and iNOS, and decreasing GSH and GPX activity, subsequently aggravating lipid peroxidation and triggering ferroptosis in triple-negative breast cancer cells.	18alpha-glycyrrhetinic acid	16-18	nitric oxide synthase 2	Homo sapiens	98-102	
33384302-7	2021	Pharmacologic inhibition of Cx43 with 18beta-Glycyrrhetinic acid (18beta-GA) exhibits a negative inotropic effect on the myometrium in a dose-dependent manner, as does administration of nebivolol, a nitric oxide synthase (NOS) activator that increases total protein SNOs.	18alpha-glycyrrhetinic acid	66-75	nitric oxide synthase 2	Homo sapiens	199-220